Sleep And Consciousness

Foundations and mechanisms

Neurobiology of consciousness

Consciousness comprises arousal and awareness. Arousal depends on ascending brainstem and diencephalic systems; awareness requires integrated thalamo-cortical and cortico-cortical processing, particularly frontoparietal associative networks. This distinction is exam-critical: brainstem or bilateral thalamic injury may abolish arousal, whereas widespread cortical dysfunction may preserve wakefulness but abolish meaningful awareness.

The ascending reticular activating system is not a single tract but a distributed network arising from the pontomesencephalic tegmentum and projecting via thalamic and extrathalamic pathways to cortex. Key nuclei include the locus coeruleus, dorsal raphe, pedunculopontine and laterodorsal tegmental nuclei, tuberomammillary nucleus, basal forebrain, and lateral hypothalamic orexin neurons. Consciousness requires adequate cerebral perfusion and substrate delivery: normal cerebral blood flow is approximately 50 ml/100 g/min; EEG slowing occurs below about 20 ml/100 g/min, electrical silence at approximately 15 ml/100 g/min, and irreversible injury becomes likely below 10 ml/100 g/min if sustained.

System	Principal transmitter	Wakefulness effect	Anaesthetic relevance
Locus coeruleus	Noradrenaline	Vigilance, stress arousal, attention	Suppressed by volatile agents and propofol; enhanced by painful stimulation
Dorsal raphe	Serotonin	Wake promotion, REM suppression	REM rebound after withdrawal of sedatives or alcohol
Tuberomammillary nucleus	Histamine	Cortical activation	H1 antagonists cause sedation
Basal forebrain and PPN/LDT	Acetylcholine	Cortical desynchronisation; REM generation	Anticholinergics may cause delirium, especially in elderly patients
Ventrolateral preoptic nucleus	GABA, galanin	Sleep-active inhibition of arousal nuclei	Potentiated by propofol, volatile agents and benzodiazepines
Lateral hypothalamus	Orexin A/B	Stabilises wakefulness	Deficiency causes narcolepsy with cataplexy

Sleep architecture and scoring

Adult sleep is divided by American Academy of Sleep Medicine scoring into NREM stages N1, N2, N3 and REM sleep, scored in 30-second epochs using EEG, electro-oculography and chin electromyography. Normal adult total sleep time is typically 7–9 hours, with sleep efficiency usually >85%. Sleep cycles recur every 90–110 minutes, with increasing REM duration towards morning and greater N3 sleep in the first third of the night.

Stage	Typical proportion of adult sleep	EEG/EOG/EMG features	Physiological significance
N1	2–5%	Low-voltage mixed frequency; attenuation of posterior alpha; slow rolling eye movements	Transitional sleep; easily aroused
N2	45–55%	Sleep spindles 11–16 Hz, usually 12–14 Hz; K-complexes	Stable NREM sleep; thalamocortical gating
N3	15–25%, falls with age	Delta activity 0.5–2 Hz, amplitude ≥75 microvolts, occupying ≥20% of epoch	Slow-wave sleep; growth hormone secretion; high arousal threshold
REM	20–25%	Low-voltage mixed-frequency EEG, rapid eye movements, chin EMG atonia	Dreaming, memory consolidation, autonomic variability

NREM sleep is associated with reduced sympathetic tone, reduced heart rate and blood pressure, and relatively regular ventilation. REM sleep produces cortical activation with skeletal muscle atonia mediated through pontomedullary pathways and spinal motor neurone inhibition. Cardiovascular and respiratory instability are greatest during REM: phasic sympathetic bursts, irregular respiratory rhythm and increased propensity to upper airway collapse are clinically relevant in obstructive sleep apnoea.

Circadian and homeostatic regulation

Sleep timing reflects interaction between Process C, the circadian pacemaker in the suprachiasmatic nucleus, and Process S, homeostatic sleep pressure. Light entrains the suprachiasmatic nucleus via intrinsically photosensitive retinal ganglion cells containing melanopsin, maximally sensitive to blue light around 460–480 nm. Melatonin secretion from the pineal gland rises in dim light, usually beginning around 21:00–22:00, peaks at approximately 02:00–04:00, and is suppressed by nocturnal light exposure.

Adenosine accumulation during wakefulness contributes to sleep pressure, particularly through A1 and A2A receptors; caffeine is a competitive adenosine receptor antagonist with a typical adult elimination half-life of 3–7 hours, prolonged in pregnancy and hepatic impairment. Orexin stabilises the wake state; low cerebrospinal fluid orexin-A, classically <110 pg/ml or less than one-third of normal mean values, supports narcolepsy type 1 in the correct clinical context.

Altered consciousness, coma and anaesthesia

Reduced consciousness results from failure of arousal systems, bilateral hemispheric dysfunction, or systemic derangements impairing neuronal metabolism. Important physiological causes include hypoxaemia, hypercapnia, hypoglycaemia, hyperosmolarity, hepatic or uraemic encephalopathy, sepsis, hypothermia and drug effects. The Glasgow Coma Scale ranges from 3 to 15; a score of ≤8 is conventionally associated with inability to protect the airway, although airway decisions must incorporate trajectory, aspiration risk, gas exchange and anticipated intervention.

General anaesthesia represents a drug-induced, reversible state characterised by unconsciousness, amnesia, immobility and autonomic modulation. Mechanistically, most hypnotic agents enhance inhibitory GABA_A signalling, suppress excitatory NMDA or nicotinic transmission, disrupt thalamo-cortical connectivity and reduce frontoparietal information integration. Propofol produces hypnosis principally via GABA_A potentiation; induction dose is commonly 1.5–2.5 mg/kg IV in healthy adults, reduced in elderly, shocked or hypovolaemic patients. Midazolam is a benzodiazepine GABA_A positive allosteric modulator; typical anxiolytic premedication is 1–2 mg IV titrated, with context-sensitive prolongation after repeated dosing. Ketamine, an NMDA antagonist, can produce dissociative anaesthesia while preserving airway reflexes and sympathetic tone; induction dose is approximately 1–2 mg/kg IV or 4–6 mg/kg IM.

Processed EEG indices such as BIS attempt to quantify hypnotic effect; a BIS of 40–60 is commonly targeted during general anaesthesia, but values are unreliable with ketamine, nitrous oxide, neuromuscular blockade, hypothermia, artefact and severe cerebral pathology. Thus, consciousness is best understood physiologically as an emergent property of arousal networks, cortical integration and metabolic viability rather than a single measurable variable.

Clinical assessment and investigations

Clinical presentation and structured bedside assessment

Disturbance of consciousness should be described by arousal and awareness, rather than vague terms such as “drowsy”. Arousal reflects ascending reticular activating system, thalamic and hypothalamic wake-promoting activity; awareness requires integrated cortico-thalamo-cortical function. Clinically, presentations range from physiological sleep to delirium, drug-induced hypnosis, coma, unresponsive wakefulness syndrome and brain death. In perioperative and critical care practice, the key distinction is often between reversible depression of arousal, structural brain injury, metabolic encephalopathy, non-convulsive status epilepticus and residual anaesthetic or sedative effect.

Tool	Components	Interpretation and thresholds	Limitations
GCS	Eye 1–4, verbal 1–5, motor 1–6; total 3–15	≤8 conventionally defines coma and need to consider airway protection; motor score is most prognostic. Fall ≥2 points is clinically significant.	Confounded by tracheal intubation, aphasia, facial trauma, sedation, neuromuscular blockade.
FOUR score	Eye, motor, brainstem reflexes, respiration; each 0–4	Better than GCS in intubated patients; incorporates pupillary/corneal reflexes and respiratory pattern.	Requires familiarity; less universally embedded.
RASS	Agitation-sedation scale from +4 to −5	ICU target commonly −2 to 0 for light sedation; −5 indicates no response to voice or physical stimulation.	Does not diagnose delirium; affected by paralysis and hearing impairment.
CAM-ICU / ICDSC	Acute change, inattention, altered level, disorganised thinking	CAM-ICU specificity approximately 95%, sensitivity variable 47–80% in routine practice; use only if RASS ≥ −3.	False negatives with deep sedation, aphasia, severe dementia.

Differential diagnosis

Assessment begins with ABCDE, glucose, temperature, pupils, focal neurology, meningism, toxidrome and medication reconciliation. Important pharmacological causes include opioids, benzodiazepines, propofol, volatile agents, ketamine, alpha-2 agonists, anticholinergics, anticonvulsants and alcohol. Flumazenil 200 micrograms IV increments may reverse benzodiazepine effect but risks seizures in dependence or mixed overdose; naloxone 40–100 micrograms IV titrated to ventilation avoids abrupt sympathetic surge. Residual neuromuscular blockade may mimic coma; train-of-four ratio should be ≥0.9 before assuming adequate recovery.

Category	Examples	Clues	Priority investigations
Structural	Intracranial haemorrhage, infarct, tumour, hydrocephalus	Focal signs, anisocoria, trauma, anticoagulation	Urgent CT brain ± CT angiography; MRI diffusion for early ischaemia
Metabolic/endocrine	Hypoglycaemia, hyponatraemia, hypercapnia, hepatic/uraemic encephalopathy, myxoedema	Asterixis, hypothermia, acid-base disturbance	ABG/VBG, U&E, LFT, ammonia, osmolality, thyroid/adrenal tests when indicated
Infective/inflammatory	Meningitis, encephalitis, sepsis-associated encephalopathy, autoimmune encephalitis	Fever, rash, seizures, psychiatric prodrome	Blood cultures, CRP, CT before LP if focal signs/raised ICP risk; CSF, PCR, autoimmune panel
Electrical	Non-convulsive status epilepticus, post-ictal state	Fluctuating coma, subtle twitching, eye deviation	Urgent EEG; continuous EEG in refractory coma
Sleep-related	OSA, central sleep apnoea, narcolepsy, parasomnias, circadian disorder	Daytime somnolence, witnessed apnoea, cataplexy, REM phenomena	Sleep questionnaires, oximetry, polysomnography, MSLT

Investigations of sleep disorders

For sleep-disordered breathing, screening tools such as STOP-Bang are useful perioperatively: score ≥3 is sensitive for obstructive sleep apnoea, while ≥5 indicates high risk of moderate-to-severe OSA. Excessive daytime sleepiness is quantified with the Epworth Sleepiness Scale; normal is usually <10, 10–15 suggests abnormal sleepiness, and >16 severe sleepiness. Definitive testing is overnight polysomnography, recording EEG, electro-oculography, submental and limb EMG, airflow, respiratory effort, oximetry, ECG and body position.

Index	Definition	Diagnostic thresholds
AHI	Apnoeas + hypopnoeas per hour of sleep	Normal <5 h−1; mild 5–14.9; moderate 15–29.9; severe ≥30
Apnoea	≥90% reduction in airflow for ≥10 s	Obstructive if effort persists; central if effort absent
Hypopnoea	Reduced airflow for ≥10 s with desaturation or arousal	AASM scoring commonly uses ≥3% desaturation or arousal; some payers require ≥4%
ODI	Oxygen desaturations per hour, usually ≥3% or ≥4%	Useful for home oximetry but underestimates arousal-dominant disease

Narcolepsy is investigated with nocturnal polysomnography followed by multiple sleep latency testing. Diagnostic criteria require mean sleep latency ≤8 minutes and ≥2 sleep-onset REM periods, after excluding insufficient sleep, circadian misalignment, sedatives and untreated OSA. CSF hypocretin-1 <110 pg ml⁻¹ or <1/3 normal supports narcolepsy type 1. REM sleep behaviour disorder shows REM sleep without atonia on EMG and is strongly associated with synucleinopathy.

EEG, processed EEG and coma prognostication

EEG distinguishes sleep stages and pathological unconsciousness. Wakefulness shows posterior alpha 8–13 Hz; N1 low-voltage theta 4–7 Hz; N2 sleep spindles 11–16 Hz and K-complexes; N3 delta 0.5–2 Hz occupying ≥20% of an epoch; REM has low-amplitude mixed frequency EEG with atonia. Anaesthetic hypnosis produces drug-specific patterns: propofol and volatile agents commonly generate frontal alpha with slow-delta oscillations, whereas ketamine may increase high-frequency activity despite dissociation.

Processed EEG indices, including BIS, are dimensionless proprietary transformations. BIS 40–60 is commonly targeted for general anaesthesia; values <40 indicate deep hypnosis or burst suppression, although artefact, EMG, ketamine, nitrous oxide, cerebral ischaemia and hypothermia reduce reliability. The B-Aware trial reported reduced explicit awareness in high-risk patients using BIS-guided anaesthesia, but later pragmatic trials showed less consistent benefit when end-tidal anaesthetic concentration monitoring was used.

In post-cardiac arrest coma, prognostication should be multimodal and delayed until ≥72 hours after return of spontaneous circulation or rewarming, with sedatives cleared. Highly malignant EEG patterns include suppressed background <10 microvolts and burst suppression, particularly after 24 hours. Bilaterally absent N20 somatosensory evoked potentials after 24–72 hours have very high specificity for poor outcome, but false positives occur with technical error and hypothermia.

Management, pharmacology and procedures

Acute management of impaired consciousness

Management is physiology-led: preserve cerebral oxygen delivery, treat reversible causes, and avoid secondary neuronal injury. Initial priorities are airway protection, normoxaemia, normocapnia, haemodynamic support and rapid exclusion of hypoglycaemia, opioid toxicity, sedative overdose, sepsis, seizures and raised intracranial pressure. A pragmatic threshold for tracheal intubation is failure to maintain airway reflexes, persistent hypoxaemia, anticipated deterioration, or GCS ≤8, although trajectory and cause are more important than the absolute score.

Intervention	Typical adult dose/target	Physiological rationale and cautions
Oxygenation and ventilation	SpO2 94–98%; PaO2 >10 kPa; PaCO2 4.5–5.0 kPa	Hypoxaemia and hypercapnia increase cerebral blood flow and intracranial pressure; avoid prolonged hypocapnia except transiently for impending herniation.
Glucose	25 g IV glucose after thiamine if malnourished/alcohol-dependent	Neuroglycopenia is rapidly reversible; thiamine 100–200 mg IV reduces risk of Wernicke encephalopathy.
Naloxone	40 micrograms IV increments; larger boluses 400 micrograms–2 mg if apnoeic	Competitive μ-antagonist; short half-life 30–90 min, so recurrence may occur with methadone, morphine MR or fentanyl patches.
Flumazenil	200 micrograms IV, then 100 micrograms every 60 s; usual max 1 mg	Useful for iatrogenic benzodiazepine excess; avoid in mixed overdose, epilepsy or benzodiazepine dependence due to seizures.
Raised ICP	Head-up 30°, MAP to maintain CPP 60–70 mmHg; hypertonic saline 3% 2–3 ml/kg or mannitol 0.25–1 g/kg	Osmotherapy lowers brain water; monitor sodium/osmolality, renal function and haemodynamics.
Status epilepticus	Lorazepam 0.1 mg/kg IV, then levetiracetam 60 mg/kg IV or phenytoin 20 mg/kg IV	Non-convulsive status is a frequent cause of coma; EEG confirmation should not delay treatment.

Sedation, anaesthesia and manipulation of consciousness

General anaesthesia is a pharmacologically induced, reversible state comprising hypnosis, amnesia, immobility, antinociception and autonomic stability. These components are separable: immobility is predominantly spinal, whereas hypnosis/amnesia reflect thalamocortical and frontoparietal network disruption. Most hypnotics potentiate GABA_A inhibition; ketamine is primarily NMDA antagonistic and preserves airway reflexes and sympathetic tone; dexmedetomidine activates α₂-adrenoceptors in the locus coeruleus, producing a sleep-like, rousable sedation.

Drug/class	Common dose	Key pharmacology relevant to consciousness
Propofol	Induction 1.5–2.5 mg/kg IV; sedation 0.3–4 mg/kg/h	Rapid redistribution; context-sensitive half-time rises with infusion duration. Produces beta activation then slow-delta EEG and burst suppression at high concentrations. Complications: hypotension, apnoea, hypertriglyceridaemia and propofol infusion syndrome, especially >4 mg/kg/h for >48 h.
Midazolam	0.5–2 mg IV increments; infusion 0.02–0.1 mg/kg/h	GABAA positive allosteric modulator; active metabolite accumulates in renal failure, prolonging coma and delirium risk.
Dexmedetomidine	0.2–1.4 micrograms/kg/h; loading often omitted	Minimal respiratory depression; useful for cooperative ICU sedation and extubation, but causes bradycardia and hypotension.
Ketamine	0.5–2 mg/kg IV; analgesic infusion 0.05–0.3 mg/kg/h	Dissociative anaesthesia with thalamocortical disruption; increases secretions and may cause emergence phenomena; haemodynamic support depends on catecholamine reserve.
Volatile agents	MAC: sevoflurane approximately 2.0%, isoflurane 1.15%, desflurane 6%	MAC decreases about 6% per decade after age 40 and is reduced by opioids, benzodiazepines, hypothermia and pregnancy. Suppress REM and slow-wave sleep postoperatively.

ICU sedation should be titrated to explicit targets, commonly RASS 0 to −2 unless deep sedation is indicated for severe ARDS, refractory intracranial hypertension or neuromuscular blockade. PADIS guidelines favour propofol or dexmedetomidine over benzodiazepines for mechanically ventilated adults because benzodiazepines increase delirium and ventilation duration. Delirium surveillance with CAM-ICU or ICDSC should be routine; non-pharmacological measures include sleep preservation, early mobilisation, reorientation, sensory aids and minimisation of deliriogenic drugs. Antipsychotics do not shorten delirium duration but may be used for dangerous agitation at the lowest effective dose, with QT and extrapyramidal monitoring.

Sleep disorders: procedures and treatment

Polysomnography remains the reference investigation when diagnosis is uncertain, disease is severe, or there are cardiorespiratory comorbidities. It records EEG, EOG, chin/limb EMG, airflow, respiratory effort, oximetry and ECG. Obstructive sleep apnoea is graded by the apnoea–hypopnoea index: mild 5–14.9/h, moderate 15–29.9/h, severe ≥30/h. STOP-Bang ≥3 is sensitive for OSA but poorly specific; perioperative risk rises with severe OSA, obesity hypoventilation, opioid use and difficult airway predictors.

Condition	Management	Follow-up/complications
OSA	Weight loss, alcohol/sedative avoidance, positional therapy; CPAP usually first-line for symptomatic moderate–severe disease. Perioperatively use opioid-sparing analgesia, cautious sedation and postoperative CPAP where established.	Assess adherence, residual AHI and mask leak. Untreated OSA increases hypertension, arrhythmia, pulmonary hypertension and postoperative respiratory events.
Insomnia	CBT-I first-line. Short courses only: zopiclone 3.75–7.5 mg nocte or zolpidem 5–10 mg nocte.	Hypnotics cause tolerance, falls, cognitive impairment and parasomnias; avoid long-term prescribing and in untreated OSA where possible.
Narcolepsy	Modafinil 100–200 mg morning/noon; methylphenidate or amphetamines specialist-led; sodium oxybate for cataplexy in selected patients.	Multiple sleep latency test: mean sleep latency ≤8 min with ≥2 sleep-onset REM periods supports diagnosis. Consider interactions with anaesthetic drugs and perioperative continuation plans.
REM sleep behaviour disorder	Environmental safety; melatonin 2–12 mg nocte or clonazepam 0.25–1 mg nocte.	May precede α-synucleinopathies; neurological follow-up is appropriate.

Prognostication and specialist procedures

Persistent coma requires structured reassessment: drug clearance, metabolic correction, neuroimaging, EEG and consideration of lumbar puncture when infection or inflammation is suspected and mass lesion excluded. Prognostication after cardiac arrest should be delayed until at least 72 h after return of spontaneous circulation and after confounders such as sedation, hypothermia and metabolic derangement have resolved. Bilaterally absent pupillary/corneal reflexes, absent N20 somatosensory evoked potentials, highly malignant EEG patterns, neuron-specific enolase trends and imaging should be interpreted multimodally. Death by neurological criteria requires a known irreversible cause, exclusion of confounders, and formal brainstem testing according to national standards.

Exam controversies and advanced synthesis

Sleep, anaesthesia and consciousness: avoid false equivalence

A common viva pitfall is to describe general anaesthesia as “sleep”. Natural sleep is an actively regulated, reversible behavioural state with cycling through AASM stages scored in 30-second epochs using EEG, EOG and submental EMG: N1, N2, N3 and REM. General anaesthesia is a drug-induced state comprising variably expressed hypnosis, amnesia, antinociception, autonomic stability and immobility. Immobility to surgical stimulus is predominantly spinal; hence MAC is not a cortical consciousness measure. REM sleep shows cortical activation with skeletal atonia and vivid mentation, whereas propofol and volatile anaesthesia typically produce frontal alpha coherence, slow-delta oscillations and thalamocortical disconnection.

State	EEG/physiology	Exam-relevant distinction
NREM N3	Slow-wave activity, high arousal threshold, reduced sympathetic tone	Physiological, cyclical; memory processing and restorative functions preserved
REM	Low-voltage mixed-frequency EEG, rapid eye movements, muscle atonia	Brain metabolically active; autonomic instability; dreams common
Propofol/volatile anaesthesia	Frontal alpha, delta oscillations; reduced effective connectivity	Drug concentration-dependent unconsciousness; not normal sleep architecture
Ketamine	High-frequency activity, dissociation, preserved airway reflexes variably	Processed EEG may overestimate consciousness or give paradoxically high values

Processed EEG: useful adjunct, not a consciousness monitor

The BIS scale is empirically derived: 100 awake, 40–60 usually targeted for general anaesthesia, <40 suggesting deep hypnosis or burst suppression. However, BIS is not a direct measure of awareness. It is vulnerable to EMG contamination, hypothermia, cerebral ischaemia, ketamine, nitrous oxide, xenon, opioids and electrical artefact. The viva synthesis is that processed EEG estimates cortical hypnotic effect, whereas awareness depends on drug delivery, patient risk, stimulus intensity, amnesia and recall.

Trial / dataset	Population	Key finding	Interpretation
B-Aware 2004	High-risk patients	BIS guidance reduced awareness: approximately 0.17% vs 0.91%	Supports BIS in selected high-risk cases
B-Unaware 2008	High-risk volatile anaesthesia	BIS not superior to end-tidal anaesthetic concentration protocols	Maintaining adequate age-adjusted MAC is at least as important
BAG-RECALL 2011	High-risk volatile anaesthesia	No clear superiority of BIS over ETAC alarms; awareness remained rare	ETAC monitoring is a robust comparator when volatiles are used
NAP5 UK/Ireland	National audit	Patient-reported accidental awareness about 1:19,000 anaesthetics; higher with neuromuscular blockade, approximately 1:8,000	Risk clusters around induction, transfer, TIVA failure and paralysis

Guideline-consistent answers should state that volatile anaesthesia requires continuous agent analysis with low-agent alarms; many departments use end-tidal age-adjusted MAC targets of approximately 0.7–1.3 MAC during maintenance. Processed EEG is most defensible for TIVA with neuromuscular blockade, high-risk awareness patients, major cardiac/obstetric cases, haemodynamic limitation of anaesthetic dose, and when clinical signs are unavailable. It should not replace checking vapouriser, infusion pump, cannula patency, syringe concentration and neuromuscular monitoring.

Pharmacological controversies: sleep quality, delirium and sedation depth

ICU and perioperative sedation illustrate the interface between sleep and consciousness. Benzodiazepines produce anterograde amnesia but disrupt sleep architecture, suppress slow-wave sleep, reduce REM and increase delirium risk. Propofol provides titratable hypnosis but is not restorative sleep; typical ICU infusion rates are 0.3–4 mg kg⁻¹ h⁻¹, with rapid redistribution but context-sensitive accumulation. Dexmedetomidine, an α₂-agonist, produces cooperative sedation resembling aspects of N2 sleep via locus coeruleus inhibition; usual infusion is 0.2–1.4 micrograms kg⁻¹ h⁻¹, elimination half-life about 2 hours, with bradycardia and hypotension limiting use.

Modern ICU guidelines favour light sedation where feasible, daily sedation interruption or protocolised sedation, analgesia-first strategies, and validated scales. RASS ranges from +4 combative to −5 unrousable; many ventilated patients are targeted to −2 to 0 unless severe respiratory failure, raised ICP, status epilepticus or neuromuscular blockade mandates deeper sedation. Delirium screening with CAM-ICU or ICDSC is recommended, but sensitivity falls outside trial conditions; a negative CAM-ICU does not exclude hypoactive delirium in a deeply sedated patient.

Obstructive sleep apnoea and perioperative consciousness risk

OSA is often tested because it links sleep physiology, airway mechanics and anaesthetic pharmacology. AHI defines severity: mild 5–14.9 h⁻¹, moderate 15–29.9 h⁻¹, severe ≥30 h⁻¹. STOP-Bang ≥3 is sensitive but poorly specific; thresholds ≥5 improve specificity for moderate–severe OSA. Anaesthetic implications include heightened opioid sensitivity, difficult mask ventilation/intubation, postoperative obstruction, REM rebound around nights 3–5, and risk when residual neuromuscular blockade coexists with sedatives. The exam answer should emphasise opioid-sparing multimodal analgesia, full reversal confirmed quantitatively with train-of-four ratio ≥0.9, CPAP continuation, positioning and monitored recovery.

Brain death, coma and scoring pitfalls

Consciousness assessment must distinguish arousal from awareness. GCS is limited by intubation, aphasia, orbital trauma and sedatives; the FOUR score adds brainstem reflexes and respiratory pattern. Brainstem death testing is jurisdiction-specific but requires an irreversible cause of coma and exclusion of confounders: sedatives, neuromuscular blockade, severe metabolic disturbance and hypothermia. UK practice requires core temperature >34°C, absence of drug effect, two qualified doctors and demonstration of absent brainstem reflexes plus apnoea despite a sufficient hypercapnic stimulus, commonly PaCO₂ ≥6.5 kPa. Do not diagnose death by neurological criteria in drug intoxication, post-cardiac arrest hypothermia, or profound endocrine/metabolic derangement without appropriate delay or ancillary testing.

High-yield viva synthesis

• Natural sleep is staged; anaesthesia is titrated. EEG resemblance does not imply identical physiology.
• Awareness prevention is systems-based: drug delivery, ETAC, infusion integrity, neuromuscular monitoring and documentation.
• BIS 40–60 is a guide, not a guarantee; ketamine, nitrous oxide and EMG can mislead.
• Light ICU sedation improves outcomes when clinically appropriate, but agitation, hypoxaemia and raised ICP may justify deeper targets.
• Residual paralysis can mimic unconsciousness; always separate motor response from awareness.